Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Surgical Oncology

Anatomy and Staging: The Role of Blood Vessels

At a Glance

For pancreatic cancer, the tumor’s relationship to nearby major blood vessels and any distant spread helps determine whether it can be removed safely. A pancreas-protocol CT, sometimes with liver MRI, guides decisions about surgery, chemotherapy first, or systemic treatment.

In many cancers, “staging” is just about how large a tumor is or how many lymph nodes it has reached. In pancreatic cancer, however, the most important local-anatomic factor is resectability—a classification that describes whether a surgeon can safely remove the tumor based on its relationship to nearby major blood vessels [1][2]. This mapping dictates much of your initial treatment path, determining whether you start with surgery or with chemotherapy.

The Importance of Pancreas-Protocol Imaging

To get an accurate map, your doctors need a specialized scan called a pancreas-protocol CT. Unlike a standard CT, this scan uses very thin “slices” and timed IV contrast to capture the pancreas when blood flow through the arteries and veins is at its peak [3][4]. This allows radiologists to see exactly how much of a vessel’s circumference is touched by the tumor, measured in degrees (e.g., less than or more than 180°) [1]. In some cases, a liver MRI may also be used to double-check for small spots that a CT might miss [5][3].

The Categories of Resectability

Your team will assess your cancer based on your scans. These categories describe the local anatomy, provided there is no distant spread.

  1. Resectable: The tumor does not touch any major arteries (like the SMA or Celiac Axis) and has minimal or no contact with major veins (like the Portal Vein or SMV) [6][2]. In these cases, upfront surgery may be an option, provided there is no metastatic spread.
  2. Borderline Resectable: The tumor is “leaning” against one or more major vessels. It may abut a vessel or cause some narrowing of a vein [1][7]. While surgery might be possible, it is difficult to get “clean margins” (removing all cancer cells) immediately. Most patients in this group receive chemotherapy first (neoadjuvant therapy) to shrink the tumor away from the vessels [8][9].
  3. Locally Advanced (Unresectable): The tumor has extensively involved a major artery or has blocked a vein so severely it cannot be reconstructed safely [7][9]. Surgery is generally not safe as an initial step, and the focus is on intensive systemic treatment to control the disease locally.
  4. Metastatic: The cancer has spread to distant organs, such as the liver, lungs, or the lining of the abdomen (peritoneum) [1]. In this stage, surgery to remove the primary tumor in the pancreas is usually not performed because the focus shifts to treating the cancer throughout the entire body.

Anatomic vs. TNM Staging

You may also see an AJCC TNM stage (e.g., T2N1M0) on your reports. While these numbers remain highly important to help doctors predict long-term outlooks (prognosis) and guide systemic treatment, they do not always tell the full story of what a surgeon can do [1][10].

  • T (Tumor): Size of the tumor and where it has grown [11].
  • N (Node): Whether the cancer has spread to nearby lymph nodes [11].
  • M (Metastasis): Whether it has spread to other organs [11].

Because imaging sometimes “under-stages” the disease—missing tiny cells in lymph nodes—your surgical team relies heavily on the resectability categories described above alongside TNM to decide if, when, and how to operate [10].

Why Vessels Matter

The pancreas is surrounded by a “highway system” of critical blood vessels that supply blood to your intestines and liver. Contact thresholds depend on contour irregularity, occlusion, and institutional criteria.

  • Arteries (SMA, Celiac Axis): These carry oxygen-rich blood. If a tumor wraps too tightly around them, they cannot be safely cut and sewn back together [7].
  • Veins (Portal Vein, SMV): These carry blood away from the intestines. Surgeons at high-volume centers can often “reconstruct” these veins by removing a piece and replacing it with a graft if the tumor involvement is limited [1][12]. This is why vein involvement is often considered “borderline” while heavy artery involvement is more likely to be “locally advanced.”

Common questions in this guide

What does resectability mean in pancreatic cancer?
Resectability describes whether a surgeon can safely remove the pancreatic tumor based on its relationship to nearby major blood vessels and whether the cancer has spread elsewhere. It helps determine whether surgery can come first or whether chemotherapy or another treatment should be used before surgery.
Why do I need a pancreas-protocol CT?
A pancreas-protocol CT uses very thin slices and timed intravenous contrast to show the pancreas and nearby arteries and veins in detail. It helps the team measure how much of a vessel’s circumference the tumor touches and assess whether surgery may be possible.
What is the difference between resectable, borderline resectable, and locally advanced pancreatic cancer?
Resectable tumors have little or no involvement of major vessels and may be removable with upfront surgery if there is no distant spread. Borderline-resectable tumors touch or narrow vessels and often receive treatment first, while locally advanced tumors extensively involve an artery or an unreconstructible vein and are generally not removed initially.
Can pancreatic cancer involving a blood vessel still be operated on?
Sometimes yes, particularly when involvement is limited to a vein that an experienced surgeon can reconstruct. Extensive involvement of major arteries or a vein that cannot be safely reconstructed may make initial surgery unsafe, so the decision depends on detailed imaging and specialist review.
How is TNM staging different from resectability?
TNM staging describes the tumor’s size and local growth, nearby lymph nodes, and spread to distant organs. Resectability focuses on the anatomy around the tumor—especially major blood vessels—so a person’s TNM stage does not by itself determine whether surgery is possible.
Why might chemotherapy be given before surgery for borderline-resectable pancreatic cancer?
Chemotherapy given before surgery is called neoadjuvant therapy and may help control the cancer and shrink or stabilize its relationship to nearby vessels. After treatment, the team reassesses the scans to determine whether safe surgery with clear margins is possible.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my CT scan follow the 'pancreas protocol' with thin slices to best see the blood vessels?
  2. 2.Based on the NCCN criteria, is my tumor classified as resectable, borderline resectable, or locally advanced?
  3. 3.Which specific blood vessels—like the SMA, Celiac Axis, or Portal Vein—are involved, and is there 'encasement' or just 'abutment'?
  4. 4.If my tumor is borderline, is the vein involvement reconstructible, and will we use neoadjuvant therapy to try to shrink it first?
  5. 5.Did the radiologist see any 'indeterminate' spots on my liver that might require a follow-up MRI for clarification?
  6. 6.What was my AJCC TNM stage, and how does that relate to the surgical plan you are proposing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.

    Isaji S, Mizuno S, Windsor JA, et al.

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2018; (18(1)):2-11 doi:10.1016/j.pan.2017.11.011.

    PMID: 29191513
  2. 2

    White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.

    Kulkarni NM, Soloff EV, Tolat PP, et al.

    Abdominal radiology (New York) 2020; (45(3)):716-728 doi:10.1007/s00261-019-02289-5.

    PMID: 31748823
  3. 3

    Use of imaging as staging and surgical planning for pancreatic surgery.

    Nguyen AH, Melstrom LG

    Hepatobiliary surgery and nutrition 2020; (9(5)):603-614 doi:10.21037/hbsn.2019.05.04.

    PMID: 33163511
  4. 4

    Updates on Imaging Assessment of Pancreatic Cancer for Determining Anatomic and Biologic Resectability.

    Lee SS, Kim DW, Lee W, Kim KP

    Korean journal of radiology 2026; (27(7)):634-651 doi:10.3348/kjr.2026.0341.

    PMID: 42252995
  5. 5

    Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer.

    Kim HW, Lee JC, Paik KH, et al.

    Surgery 2017; (161(6)):1579-1587 doi:10.1016/j.surg.2016.12.038.

    PMID: 28237643
  6. 6

    Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer.

    Cobb W, Rozefort D, Ji C, et al.

    Oncology 2026; (104(6)):663-671 doi:10.1159/000548583.

    PMID: 41171974
  7. 7

    Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning.

    Zaky AM, Wolfgang CL, Weiss MJ, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2017; (37(1)):93-112 doi:10.1148/rg.2017160054.

    PMID: 27885893
  8. 8

    How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.

    Jeon SK, Lee JM, Lee ES, et al.

    European radiology 2022; (32(1)):56-66 doi:10.1007/s00330-021-08108-0.

    PMID: 34170366
  9. 9

    Anatomical Classification and Staging Systems of Borderline Resectable and Locally Advanced Pancreatic Cancer-A Subgroup Analysis of the NORPACT-2 Trial.

    Ghotbi J, Farnes I, Kleive D, et al.

    Annals of surgical oncology 2025; (32(12)):8856-8869 doi:10.1245/s10434-025-17527-y.

    PMID: 40461886
  10. 10

    Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer.

    Kang H, Kim SS, Sung MJ, et al.

    Cancers 2022; (14(19)) doi:10.3390/cancers14194672.

    PMID: 36230595
  11. 11

    Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.

    Allen PJ, Kuk D, Castillo CF, et al.

    Annals of surgery 2017; (265(1)):185-191 doi:10.1097/SLA.0000000000001763.

    PMID: 27163957
  12. 12

    Diagnosis and Surgical Management for Advanced Pancreatic Cancer Requiring Vascular Resection.

    Symeou S, Lolis ED, Glantzounis GK

    Diagnostics (Basel, Switzerland) 2025; (16(1)) doi:10.3390/diagnostics16010102.

    PMID: 41515597

This page explains how blood-vessel involvement and resectability affect exocrine pancreatic carcinoma staging and treatment for informational purposes only; it is not medical advice. Your pancreatic surgeon, radiologist, and oncology team should interpret your scans and recommend care for your situation.

Get notified when new evidence is published on exocrine pancreatic carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.